Brief: Larimar Therapeutics Reports Preliminary Top-Line Data From Phase 2 Trial’S 25 MG Cohort

Larimar Therapeutics

15/05/2023 12:08

May 15 (Reuters) - Larimar Therapeutics Inc  LRMR.O :
    * LARIMAR THERAPEUTICS REPORTS PRELIMINARY TOP-LINE DATA
FROM
PHASE 2 TRIAL’S 25 MG COHORT SHOWING INCREASES IN FRATAXIN
LEVELS IN PATIENTS WITH FRIEDREICH’S ATAXIA AND FIRST QUARTER
2023 FINANCIAL RESULTS
    * LARIMAR THERAPEUTICS- SAFETY DATA SHOW REPEATED
SUBCUTANEOUS
INJECTIONS OF 25 MG CTI-1601 GENERALLY WELL TOLERATED WHEN
ADMINISTERED DAILY FOR 14 DAYS
    * LARIMAR THERAPEUTICS INC- LARIMAR HAS SUBMITTED DATA ROM
PHASE 2
TRIAL’S 25 MG COHORT TO FDA AND WILL MEET WITH AGENCY TO DISCUSS
NEXT STEPS
    * LARIMAR THERAPEUTICS INC- AS OF MARCH 31, 2023, COMPANY
HAD CASH
AND CASH EQUIVALENTS TOTALING $111.5 MILLION
    * LARIMAR THERAPEUTICS INC- REPORTED A NET LOSS FOR Q1 OF
2023 OF
$6.5 MILLION, OR $0.15 PER SHARE

Source text for Eikon:  ID:nGNX17XFkN 
Further company coverage:  LRMR.O